List view / Grid view
25 May 2016 | By Victoria White, Digital Content Producer
The findings may lead to new therapeutic strategies and suggest limitations to therapies designed to eliminate amyloid plaques from Alzheimer's patient's brains...
23 May 2016 | By Victoria White, Digital Content Producer
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer's disease, according to new research...
11 April 2016 | By Victoria White, Digital Content Producer
Chemists have designed a set of molecules that promote microscopic, anatomical changes in neurons associated with the formation and retention of memories...
8 April 2016 | By Victoria White, Digital Content Producer
Researchers identified a new gene called FOXF2 which increased the risk of having a stroke due to small vessel disease in the brain...
7 April 2016 | By Victoria White, Digital Content Producer
Allergan is to license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development by Heptares...
17 March 2016 | By Victoria White
Scientists have developed a capsule containing cells that have been genetically engineered to produce antibodies against the Abeta...
17 March 2016 | By Drug Target Review
In this Drug Targets In-Depth Focus: "The alarming increase in antibioticresistant bacteria", plus "Computational methods for drug repositioning"; and "An overview of Alzheimer’s disease drug targets"...
1 March 2016 | By Victoria White
Using pexidartinib to flush away the inflammatory cells produced in reaction to beta-amyloid plaques, scientists restored memory function in test mice...
1 March 2016 | By Victoria White
The AChE peptide has been shown to drive production of both amyloid and hyperphosphorylated tau in Alzheimer's disease...
26 February 2016 | By Victoria White
Researchers have developed a targeted substance that blocks the pathogenic function of an enzyme that is partly responsible for Alzheimer’s disease without affecting its other vital functions...
16 February 2016 | By Victoria White
AbbVie has been announced as the latest Dementia Consortium partner, joining MRC Technology, Alzheimer’s Research UK, Astex, Eisai and Lilly...
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
21 January 2016 | By Victoria White
MRCT will identify projects with the greatest promise for advancement as investigational therapies and advise the Alzheimer's Association on strategies for moving them forward such that they realise the maximum potential...
13 January 2016 | By Victoria White
Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates for psychiatric diseases...
7 January 2016 | By Nicholas Jackson
Plans for the world’s first clinical trial for a vaccine targeting Alzheimer’s disease-like characteristics in those with Down's syndrome have been announced...
